2018
A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyXR-NTXExtended-release naltrexonePsychological supportOpioid use disorderHIV prevention effortsFocus groupsPerceptions of recoveryAgonist therapyOpioid withdrawalYoung PWIDOpioid antagonistPatient preferencesNew pharmacotherapiesPsychoactive medicationsInjection careerUse disordersFocus group transcriptsPWIDPrevention effortsNaltrexoneGroup transcriptsIndividual barriersTreatmentWithdrawal
2011
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. The American Journal Of Drug And Alcohol Abuse 2011, 37: 1-11. PMID: 21247284, DOI: 10.3109/00952990.2010.540279.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsDrug interactionsOpioid dependencePsychotropic medicationsPsychoactive medicationsImportant pharmacokinetic drug interactionsClasses of medicationsOpioid-dependent patientsRelevant English-language articlesClinical case seriesMedication-assisted treatmentCytochrome P450 isoenzymesImportant clinical consequencesEnglish-language articlesPharmacokinetic interaction studyCase seriesPsychiatric comorbidityEmbase databasesClinical consequencesMedicationsP450 isoenzymesBuprenorphineMethadoneLanguage articlesPsychoactive drugs